日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Discovery of a "First-in-Class" Selective Multikinase (CDK4/6/9-AURKA/B) Inhibitor, LCI133, for Neuroblastoma

发现一种“首创”的选择性多激酶(CDK4/6/9-AURKA/B)抑制剂LCI133,用于治疗神经母细胞瘤

Maddeboina, Krishnaiah; Pal, Dhananjaya; Yada, Bharath; McHale, Cody C; Singh, Sandeep K; Chhonker, Yashpal S; Dryden, Hailey L; Delara, Ritchie; Mujumdar, Vaidehi; Zhang, Qi; Murry, Daryl J; Durden, Donald L

Recent advances in multitarget-directed ligands via in silico drug discovery

近年来,基于计算机辅助药物发现的多靶点导向配体研究取得了显著进展。

Maddeboina, Krishnaiah; Yada, Bharath; Kumari, Shikha; McHale, Cody; Pal, Dhananjaya; Durden, Donald L

Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies

一种新型多轴抑制剂在侵袭性和惰性B细胞恶性肿瘤中的临床前活性

Smith, Audrey L; Pal, Dhananjaya; Martinez-Rico, Rolando; Eiken, Alexandria P; Durden, Donald L; Kutateladze, Tatiana G; El-Gamal, Dalia

PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron

PI3K-α/mTOR/BRD4抑制剂单独使用或与其他抗病毒药物联合使用,可阻断SARS-CoV-2及其相关变异株(包括Delta和Omicron)的复制。

Acharya, Arpan; Pathania, Anup S; Pandey, Kabita; Thurman, Michellie; Vann, Kendra R; Kutateladze, Tatiana G; Challagundala, Kishore B; Durden, Donald L; Byrareddy, Siddappa N

COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges

新冠肺炎与癌症合并症:治疗机遇与挑战

Pathania, Anup S; Prathipati, Philip; Abdul, Bakrudeen Aa; Chava, Srinivas; Katta, Santharam S; Gupta, Subash C; Gangula, Pandu R; Pandey, Manoj K; Durden, Donald L; Byrareddy, Siddappa N; Challagundla, Kishore B

Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia

新型双靶向PI3Kδ/BRD4抑制剂SF2535在B细胞急性淋巴细胞白血病中的临床前评价

Ruan, Yongsheng; Kim, Hye Na; Ogana, Heather A; Wan, Zesheng; Hurwitz, Samantha; Nichols, Cydney; Abdel-Azim, Nour; Coba, Ariana; Seo, Seyoung; Loh, Yong-Hwee Eddie; Gang, Eun Ji; Abdel-Azim, Hisham; Hsieh, Chih-Lin; Lieber, Michael R; Parekh, Chintan; Pal, Dhananjaya; Bhojwani, Deepa; Durden, Donald L; Kim, Yong-Mi

A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity

一种具有增强癌细胞毒性的三重作用 CDK4/6-PI3K-BET 抑制剂

Burgoyne, Adam M; Vann, Kendra R; Joshi, Shweta; Morales, Guillermo A; Vega, Francisco M; Singh, Alok; Pal, Dhananjaya; Merati, Aran B; Kutateladze, Tatiana G; Durden, Donald L

Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

巨噬细胞 Syk-PI3Kγ 抑制抗肿瘤免疫:新型双重 Syk-PI3K 抑制剂 SRX3207 可缓解肿瘤免疫抑制

Joshi, Shweta; Liu, Kevin X; Zulcic, Muamera; Singh, Alok R; Skola, Dylan; Glass, Christopher K; Sanders, P Dominick; Sharabi, Andrew B; Pham, Timothy V; Tamayo, Pablo; Shiang, Daniel; Dinh, Huy Q; Hedrick, Catherine C; Morales, Guillermo A; Garlich, Joseph R; Durden, Donald L

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

SF2523:双重PI3K/BRD4抑制剂阻断肿瘤免疫抑制并促进癌症适应性免疫反应

Joshi, Shweta; Singh, Alok R; Liu, Kevin X; Pham, Timothy V; Zulcic, Muamera; Skola, Dylan; Chun, Hyun Bae; Glass, Christopher K; Morales, Guillermo A; Garlich, Joseph R; Durden, Donald L

Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

组合疗法提升癌症免疫疗法:合理药物设计策略,同时靶向多个靶点以杀伤肿瘤细胞并激活免疫系统

Joshi, Shweta; Durden, Donald L